Next Capital Management LLC Takes $573,000 Position in Illumina, Inc. $ILMN

Posted by Brenda Bartman on Aug 15th, 2026

Next Capital Management LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 3,256 shares of the life sciences company’s stock, valued at approximately $573,000.

Several other large investors also recently added to or reduced their stakes in ILMN. Oppenheimer Asset Management Inc. bought a new stake in shares of Illumina in the 2nd quarter valued at approximately $1,670,000. Insight Wealth Strategies LLC bought a new position in shares of Illumina during the 2nd quarter valued at approximately $6,062,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Illumina during the 2nd quarter valued at approximately $223,000. FNY Investment Advisers LLC raised its holdings in Illumina by 30.0% during the 2nd quarter. FNY Investment Advisers LLC now owns 650 shares of the life sciences company’s stock valued at $114,000 after buying an additional 150 shares during the period. Finally, Elevation Wealth Partners LLC raised its holdings in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after buying an additional 84 shares during the period. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Stifel Nicolaus raised their price target on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Barclays boosted their price objective on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Royal Bank Of Canada raised their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $188.40.

Check Out Our Latest Analysis on Illumina

Insider Activity at Illumina

In related news, Director Keith A. Meister sold 283,269 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $199.61, for a total value of $56,543,325.09. Following the transaction, the director owned 2,089,425 shares of the company’s stock, valued at $417,070,124.25. This trade represents a 11.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the sale, the chief accounting officer owned 14,446 shares of the company’s stock, valued at $2,311,360. The trade was a 3.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,415,351 shares of company stock valued at $255,966,311 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Illumina Price Performance

ILMN opened at $190.89 on Friday. The business has a fifty day moving average of $183.78 and a 200 day moving average of $150.56. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $207.00. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The stock has a market cap of $28.82 billion, a P/E ratio of 35.61, a PEG ratio of 2.71 and a beta of 1.45.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the company posted $1.19 EPS. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

About Illumina

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.